Quantumup
Cantor🏁 $SPRO Overweight-$6 and said--Spero is a clinical-stage biopharmaceutical company developing SP001 (anti-CD40L mAb), with its lead indication in IgG4-Related Disease (IgG4-RD).
[IVBIY IVBXF AMGN IMVT ZBIO BMY SNY ARGX [GSK]]
Previously, Spero developed therapies in the antibiotic space. This summer, it shifted into I&I by licensing SP001 from Innovent Biologics (NC).
Spero will be investigating SP001 for the treatment of IgG4-RD (Phase 2 study starting in 2Q27) while Innovent investigates the same drug for the treatment of Sjögren's disease in China (Phase 2 study starting in early 2027).
We believe investors have yet to pick up on this new strategy, making SPRO an under-the-radar stock.
6
